LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 17

Search options

  1. Article: Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.

    Zhang, Fengwen / Zang, Trinity / Stevenson, Eva M / Lei, Xiao / Copertino, Dennis C / Mota, Talia M / Boucau, Julie / Garcia-Beltran, Wilfredo F / Jones, R Brad / Bieniasz, Paul D

    bioRxiv : the preprint server for biology

    2022  

    Abstract: Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to CD8+ cytotoxic T cells. As part of a ... ...

    Abstract Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to CD8+ cytotoxic T cells. As part of a screen to elucidate biological activities associated with individual SARS-CoV-2 viral proteins, we found that ORF7a reduced cell surface MHC-I levels by approximately 5-fold. Nevertheless, in cells infected with SARS-CoV-2, surface MHC-I levels were reduced even in the absence of ORF7a, suggesting additional mechanisms of MHC-I downregulation. ORF7a proteins from a sample of sarbecoviruses varied in their ability to induce MHC-I downregulation and, unlike SARS-CoV-2, the ORF7a protein from SARS-CoV lacked MHC-I downregulating activity. A single-amino acid at position 59 (T/F) that is variable among sarbecovirus ORF7a proteins governed the difference in MHC-I downregulating activity. SARS-CoV-2 ORF7a physically associated with the MHC-I heavy chain and inhibited the presentation of expressed antigen to CD8+ T-cells. Speficially, ORF7a prevented the assembly of the MHC-I peptide loading complex and causing retention of MHC-I in the endoplasmic reticulum. The differential ability of ORF7a proteins to function in this way might affect sarbecovirus dissemination and persistence in human populations, particularly those with infection- or vaccine-elicited immunity.
    Language English
    Publishing date 2022-05-26
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2022.05.25.493467
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.

    Zhang, Fengwen / Zang, Trinity M / Stevenson, Eva M / Lei, Xiao / Copertino, Dennis C / Mota, Talia M / Boucau, Julie / Garcia-Beltran, Wilfredo F / Jones, R Brad / Bieniasz, Paul D

    Proceedings of the National Academy of Sciences of the United States of America

    2022  Volume 119, Issue 41, Page(s) e2209042119

    Abstract: Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to ... ...

    Abstract Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to CD8
    MeSH term(s) Amino Acids ; Antigen Presentation ; CD8-Positive T-Lymphocytes/immunology ; COVID-19/immunology ; Histocompatibility Antigens Class I/immunology ; Humans ; Major Histocompatibility Complex ; Peptides ; SARS-CoV-2 ; Viral Proteins/immunology
    Chemical Substances Amino Acids ; Histocompatibility Antigens Class I ; ORF7a protein, SARS-CoV-2 ; Peptides ; Viral Proteins
    Language English
    Publishing date 2022-09-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.2209042119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

    Copertino, Dennis C / Duarte, Rodrigo R R / Powell, Timothy R / de Mulder Rougvie, Miguel / Nixon, Douglas F

    Journal of medical virology

    2020  Volume 93, Issue 1, Page(s) 187–189

    MeSH term(s) Acetates/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/virology ; Cyclopropanes/therapeutic use ; Humans ; Quinolines/therapeutic use ; SARS-CoV-2/drug effects ; Sulfides/therapeutic use
    Chemical Substances Acetates ; Anti-Inflammatory Agents ; Antiviral Agents ; Cyclopropanes ; Quinolines ; Sulfides ; montelukast (MHM278SD3E)
    Keywords covid19
    Language English
    Publishing date 2020-07-19
    Publishing country United States
    Document type Letter
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

    Copertino, Dennis C. / Duarte, Rodrigo R. R. / Powell, Timothy R. / Mulder Rougvie, Miguel / Nixon, Douglas F.

    Journal of Medical Virology ; ISSN 0146-6615 1096-9071

    2020  

    Keywords Virology ; Infectious Diseases ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    DOI 10.1002/jmv.26299
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.

    Copertino, Dennis C / Holmberg, Carissa S / Weiler, Jared / Ward, Adam R / Howard, J Natalie / Levinger, Callie / Pang, Alina Ps / Corley, Michael J / Dündar, Friederike / Zumbo, Paul / Betel, Doron / Gandhi, Rajesh T / McMahon, Deborah K / Bosch, Ronald J / Linden, Noemi / Macatangay, Bernard J / Cyktor, Joshua C / Eron, Joseph J / Mellors, John W /
    Kovacs, Colin / Benko, Erika / Bosque, Alberto / Jones, R Brad

    JCI insight

    2023  Volume 8, Issue 18

    Abstract: IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy- ... ...

    Abstract IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhances IL-15-mediated latency reversal and NK cell function by increasing STAT5 activation. We hypothesized that HODHBt would also synergize with IL-15, via STAT5, to directly enhance HIV-specific cytotoxic T cell responses. We showed that ex vivo IL-15 + HODHBt treatment markedly enhanced HIV-specific granzyme B-releasing T cell responses in PBMCs from antiretroviral therapy-suppressed (ART-suppressed) donors. We also observed upregulation of antigen processing and presentation in CD4+ T cells and increased surface MHC-I. In ex vivo PBMCs, IL-15 + HODHBt was sufficient to reduce intact proviruses in 1 of 3 ART-suppressed donors. Our findings reveal the potential for second-generation IL-15 studies incorporating HODHBt-like therapeutics. Iterative studies layering on additional latency reversal or other agents are needed to achieve consistent ex vivo reservoir reductions.
    MeSH term(s) Humans ; HIV Infections ; STAT5 Transcription Factor/metabolism ; Interleukin-15/pharmacology ; Interleukin-15/metabolism ; Virus Latency ; T-Lymphocytes, Cytotoxic ; Antineoplastic Agents/therapeutic use
    Chemical Substances HODHBt ; STAT5 Transcription Factor ; Interleukin-15 ; Antineoplastic Agents
    Language English
    Publishing date 2023-09-22
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.169028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.

    Copertino, Dennis C / Casado Lima, Bruno C / Duarte, Rodrigo R R / Powell, Timothy R / Ormsby, Christopher E / Wilkin, Timothy / Gulick, Roy M / de Mulder Rougvie, Miguel / Nixon, Douglas F

    Journal of biomolecular structure & dynamics

    2021  Volume 40, Issue 16, Page(s) 7367–7380

    Abstract: COVID-19 is the disease caused by SARS-CoV-2 which has led to 2,643,000 deaths worldwide, a number which is rapidly increasing. Urgent studies to identify new antiviral drugs, repurpose existing drugs, or identify drugs that can target the overactive ... ...

    Abstract COVID-19 is the disease caused by SARS-CoV-2 which has led to 2,643,000 deaths worldwide, a number which is rapidly increasing. Urgent studies to identify new antiviral drugs, repurpose existing drugs, or identify drugs that can target the overactive immune response are ongoing. Antiretroviral drugs (ARVs) have been tested in past human coronavirus infections, and also against SARS-CoV-2, but a trial of lopinavir and ritonavir failed to show any clinical benefit in COVID-19. However, there is limited data as to the course of COVID-19 in people living with HIV, with some studies showing a decreased mortality for those taking certain ARV regimens. We hypothesized that ARVs other than lopinavir and ritonavir might be responsible for some protection against the progression of COVID-19. Here, we used chemoinformatic analyses to predict which ARVs would bind and potentially inhibit the SARS-CoV-2 main protease (Mpro) or RNA-dependent-RNA-polymerase (RdRp) enzymes
    MeSH term(s) COVID-19/prevention & control ; HIV Infections/drug therapy ; HIV Infections/prevention & control ; Humans ; Lopinavir/pharmacology ; Pre-Exposure Prophylaxis ; RNA ; RNA-Dependent RNA Polymerase ; Ritonavir/pharmacology ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Lopinavir (2494G1JF75) ; RNA (63231-63-0) ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2021-03-18
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 49157-3
    ISSN 1538-0254 ; 0739-1102
    ISSN (online) 1538-0254
    ISSN 0739-1102
    DOI 10.1080/07391102.2021.1901144
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.

    Duarte, Rodrigo R R / Copertino, Dennis C / Iñiguez, Luis P / Marston, Jez L / Bram, Yaron / Han, Yuling / Schwartz, Robert E / Chen, Shuibing / Nixon, Douglas F / Powell, Timothy R

    Molecular medicine (Cambridge, Mass.)

    2021  Volume 27, Issue 1, Page(s) 105

    Abstract: Background: Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to individuals who are waiting ... ...

    Abstract Background: Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to individuals who are waiting to be vaccinated, particularly in less economically developed countries, where vaccine availability may be initially limited.
    Methods: We used a data-driven approach, combining results from the screening of a large transcriptomic database (L1000) and molecular docking analyses, with in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19.
    Results: Out of thousands of FDA-approved drugs considered, we observed that atorvastatin was the most promising candidate, as its effects negatively correlated with the transcriptional changes associated with infection. Atorvastatin was further predicted to bind to SARS-CoV-2's main protease and RNA-dependent RNA polymerase, and was shown to inhibit viral entry in our lung organoid model.
    Conclusions: Small clinical studies reported that general statin use, and specifically, atorvastatin use, are associated with protective effects against COVID-19. Our study corroborrates these findings and supports the investigation of atorvastatin in larger clinical studies. Ultimately, our framework demonstrates one promising way to fast-track the identification of compounds for COVID-19, which could similarly be applied when tackling future pandemics.
    MeSH term(s) Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Atorvastatin/chemistry ; Atorvastatin/pharmacology ; COVID-19/prevention & control ; Cell Line ; Coronavirus 3C Proteases/chemistry ; Coronavirus RNA-Dependent RNA Polymerase/chemistry ; Doxycycline/pharmacology ; Drug Approval ; Drug Repositioning ; Gene Expression Regulation/drug effects ; Humans ; Lung/drug effects ; Lung/virology ; Models, Biological ; Molecular Docking Simulation ; Organoids/drug effects ; Organoids/virology ; Raloxifene Hydrochloride/chemistry ; Raloxifene Hydrochloride/pharmacology ; SARS-CoV-2/drug effects ; SARS-CoV-2/physiology ; Spike Glycoprotein, Coronavirus/genetics ; Trifluoperazine/chemistry ; Trifluoperazine/pharmacology ; United States ; United States Food and Drug Administration ; Vesiculovirus/genetics ; Virus Internalization/drug effects ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Trifluoperazine (214IZI85K3) ; Raloxifene Hydrochloride (4F86W47BR6) ; Atorvastatin (A0JWA85V8F) ; Coronavirus RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; Coronavirus 3C Proteases (EC 3.4.22.28) ; Doxycycline (N12000U13O)
    Language English
    Publishing date 2021-09-09
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1283676-x
    ISSN 1528-3658 ; 1076-1551
    ISSN (online) 1528-3658
    ISSN 1076-1551
    DOI 10.1186/s10020-021-00356-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins

    Zhang, Fengwen / Zang, Trinity / Stevenson, Eva M / Lei, Xiao / Copertino, Dennis C / Mota, Talia M / Boucau, Julie / Garcia-Beltran, Wilfredo F / Jones, R. Brad F / Bieniasz, Paul D

    bioRxiv

    Abstract: Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to CD8+ cytotoxic T cells. As part of a ... ...

    Abstract Viruses employ a variety of strategies to escape or counteract immune responses, including depletion of cell surface major histocompatibility complex class I (MHC-I), that would ordinarily present viral peptides to CD8+ cytotoxic T cells. As part of a screen to elucidate biological activities associated with individual SARS-CoV-2 viral proteins, we found that ORF7a reduced cell surface MHC-I levels by approximately 5-fold. Nevertheless, in cells infected with SARS-CoV-2, surface MHC-I levels were reduced even in the absence of ORF7a, suggesting additional mechanisms of MHC-I downregulation. ORF7a proteins from a sample of sarbecoviruses varied in their ability to induce MHC-I downregulation and, unlike SARS-CoV-2, the ORF7a protein from SARS-CoV lacked MHC-I downregulating activity. A single-amino acid at position 59 (T/F) that is variable among sarbecovirus ORF7a proteins governed the difference in MHC-I downregulating activity. SARS-CoV-2 ORF7a physically associated with the MHC-I heavy chain and inhibited the presentation of expressed antigen to CD8+ T-cells. Speficially, ORF7a prevented the assembly of the MHC-I peptide loading complex and causing retention of MHC-I in the endoplasmic reticulum. The differential ability of ORF7a proteins to function in this way might affect sarbecovirus dissemination and persistence in human populations, particularly those with infection- or vaccine-elicited immunity.
    Keywords covid19
    Language English
    Publishing date 2022-05-26
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2022.05.25.493467
    Database COVID19

    Kategorien

  9. Article ; Online: Restriction Factor Expression in Vertically Infected Children Living With HIV-1.

    Bortlik, Martin / Copertino, Dennis C / Brailey, Phillip M / Beckerle, Greta A / Ormsby, Christopher E / Rosenberg, Michael G / Wiznia, Andrew A / Raposo, Rui André Saraiva / Nixon, Douglas F / de Mulder Rougvie, Miguel

    The Pediatric infectious disease journal

    2020  Volume 40, Issue 2, Page(s) 144–146

    Abstract: Introduction: Around 1.7 million children are estimated to live with HIV-1 worldwide, and about 160,000 infants are newly infected every year. Since adaptive immunity takes time to mature and develop in infants, and maternal antibodies provide limited ... ...

    Abstract Introduction: Around 1.7 million children are estimated to live with HIV-1 worldwide, and about 160,000 infants are newly infected every year. Since adaptive immunity takes time to mature and develop in infants, and maternal antibodies provide limited antiviral activity, innate and intrinsic immunity against HIV-1 in the young is of critical importance. Intrinsic restriction factors are cellular proteins that effectively inhibit HIV-1 replication in vitro, but there is limited understanding of their role in vivo, and little to no data has been reported on the expression of host restriction factors in children. We hypothesized that restriction factor expression might be particularly important in children living with HIV-1 and correlate with disease progression.
    Methods: We analyzed gene expression of APOBEC3A, APOBEC3C, APOBEC3G, APOBEC3H, SAMHD1, ISG15, CDKN1A, MX2, TRIM5, and SLFN11 by qPCR in 121 samples of CD4+ T cells from vertically infected children living with HIV-1. Cell surface expression of BST-2/tetherin and markers of CD4+ T-cell activation were analyzed by flow cytometry.
    Results: After adjusting for gender and age, BST-2/tetherin expression on CD4+ T cells showed significant positive correlation with viral load (P = 0.0006; ρ = 0.33), CD4+ T-cell activation (P < 0.0001; ρ = 0.53), CD8+ T-cell activation (P < 0.0001; ρ = 0.53), and a negative correlation with CD4+ T-cell counts (P = 0.0008; ρ = -0.33). The expression of SAMHD1 correlated negatively with markers of T-cell activation (P = 0.046; ρ = -0.22).
    Discussion: These results suggest an important role of some restriction factors in the pathogenesis of HIV-1 in children.
    MeSH term(s) Adolescent ; Biomarkers ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/physiology ; Child ; Female ; Gene Expression Regulation ; HIV Infections/metabolism ; HIV-1 ; Humans ; Infectious Disease Transmission, Vertical ; Male ; Viral Load ; Young Adult
    Chemical Substances Biomarkers
    Language English
    Publishing date 2020-12-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0000000000002924
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

    Copertino, Dennis C / Duarte, Rodrigo R R / Powell, Timothy R / de Mulder Rougvie, Miguel / Nixon, Douglas F

    J. med. virol

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #653171
    Database COVID19

    Kategorien

To top